Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some? Loibl S, Holtschmidt J. Lancet 2023 Aug 23:S0140-6736(23)01783-X. doi: 10.1016/S0140-6736(23)01783.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Loibl S, Holtschmidt J. Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some? Lancet 2023 Aug 23:S0140-6736(23)01783-X. doi: 10.1016/S0140-6736(23)01783.
PMID: 37633307